This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
NICE has issued draft guidance (Appraisal Consultation Document; issued 20th October 2017) stating it does not recommend use of lenvatinib and sorafenib as options for treating progressive, locally advanced or metastatic, differentiated thyroid cancer (papillary, follicular or Hürthle cell) in adults whose disease does not respond to radioactive iodine.